A Novel Bioluminescent Immunoassay for Detecting SARS-CoV-2 Antibodies
In this webinar, you will learn:
- How the Lumit™ Immunoassay Technology works
- The clinical performance of the Lumit™ Dx SARS-CoV-2 Immunoassay
- The benefits of Lumit™ Immunoassay Technology and how it can increase testing capacity
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and was declared a pandemic by WHO (World Health Organization) on March 11, 2020. A key to containing the spread of COVID-19 is the ability to understand the true extent of COVID-19 infection by identifying asymptomatic cases as well as individuals who have antibodies against SARS-CoV-2,which may indicate whether individuals had been exposed to, and mounted an immune response to, the virus. Serological tests that can detect antibodies against SARS-CoV-2 can be important in understanding the prevalence and aid in designing containment strategies for this deadly disease.
In this webinar Nidhi Nath, PhD will discuss the features of the Lumit™ Dx SARS-CoV-2 Immunoassay, which is a simple, reliable, no-wash alternative to conventional ELISAs designed for qualitative detection of SARS-CoV-2 antibodies in serum or plasma. He will also discuss the clinical sensitivity (PPA) of the Lumit™ Dx Immunoassay which was stratified based on days post onset of symptoms using samples collected from subjects who tested positive for SARS-CoV-2 with an RT-PCR method and experienced varying levels of disease. In addition, Dr. Nath will discuss the clinical specificity (NPA) of the Lumit™ Immunoassay, as determined using sampled collected prior to January 2020 as well as samples collected from subjects exhibiting other illnesses.
Nidhi Nath, PhD
Senior Research Scientist
We love to talk science.
Sign up to receive monthly invitations to our webinars.